Skip to main content Back to Top
Advertisement

8/16/2019

Latanoprost Ophthalmic Solution

Products Affected - Description

    • Latanoprost ophthalmic solution, Akorn, 0.005% (50 mcg/mL), 2.5 mL bottle, NDC 17478-0625-12 - discontinued
    • Latanoprost ophthalmic solution, Greenstone, 0.005% (50 mcg/mL), 2.5 mL bottle, NDC 59762-0333-02
    • Latanoprost ophthalmic solution, Rising Pharmaceuticals, 0.005% (50 mcg/mL), 2.5 mL bottle, NDC 64980-0516-25

Reason for the Shortage

    • Akorn has discontinued latanoprost ophthalmic solution.
    • Bausch Health has latanoprost ophthalmic solution available.
    • Greenstone did not provide a reason for the shortage.
    • Rising did not provide a reason for the shortage.
    • Sandoz (Falcon) has latanoprost ophthalmic solution available.

Available Products

    • Latanoprost ophthalmic solution, Bausch Health, 0.005% (50 mcg/mL), 2.5 mL bottle, NDC 24208-0463-25
    • Latanoprost ophthalmic solution, Sandoz, 0.005% (50 mcg/mL), 2.5 mL bottle, 3 count, NDC 61314-0547-03
    • Latanoprost ophthalmic solution, Sandoz, 0.005% (50 mcg/mL), 2.5 mL bottle, NDC 61314-0547-01

Estimated Resupply Dates

    • Greenstone has latanoprost ophthalmic solution on back order and the company cannot estimate a release date.
    • Rising has latanoprost ophthalmic solution on allocation.

Updated

Updated August 16, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created January 3, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins